Dedifferentiated liposarcoma is a fast-growing and more aggressive type of soft tissue sarcoma that originates as a well-differentiated sarcoma and has a typical diagnosis age of 40 to 60 years. DDLPS ...

Please provide your email address to receive an email when new articles are posted on . Milademetan failed to significantly extend PFS among patients with dedifferentiated liposarcoma, according to ...

Phase 1 trial of seclidemstat (SP-2577) in patients with relapsed/refractory Ewing sarcoma. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract does not include a full ...

Please provide your email address to receive an email when new articles are posted on . Administration of the MDM2 inhibitor milademetan in an intermittent dosing schedule mitigated dose-limiting ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Rain Oncology is a late-stage oncology company. Their lead product, milademetan, is an oral inhibitor of the MDM2-p53. In the past, MDM2 inhibitors have been associated with severe hematologic events.

In part 3 of an interview, MD Anderson’s Ravin Ratan, MD, MEd, discusses neoadjuvant immune checkpoint blockade for 2 specific types of soft tissue sarcomas. Liposarcomas originate in fat cells and ...

NEWARK, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics with its lead product candidate, ...

Rain Oncology has milademetan in several trials. The oral therapy didn't show a big advantage over the current standard of care in treating dedifferentiated liposarcoma. The company has enough cash to ...

Esophageal liposarcoma and fibrovascular polyps represent rare but clinically significant tumours of the oesophagus. Traditionally, fibrovascular polyps have been considered benign, pedunculated ...